Purinex, Inc.

2017 ◽  
pp. 1-11
Author(s):  
Robert F. Bruner ◽  
Sean Carr
Keyword(s):  
Pharmaceutical Company ◽  
The Other ◽  
Leading Compounds ◽  
Major Pharmaceutical Company

In June 2004 Purinex, Inc., a pharmaceutical company with several clinically and commercially promising drugs in development, expected to secure a partnership with a major pharmaceutical company sometime in the next four to 12 months. That partnership, if secured, would enable Purinex to develop one of its leading compounds as a drug. The company, however, had no sales or earnings and only 11 months of cash on hand. The student must assess whether the company should attempt to secure financing now or wait until it consummated a partnership deal. The tasks for the student include evaluating the probabilities that collaboration with a pharmaceutical company would actually happen; determining whether the company stay above water until such occurred; and analyzing the other risks to the company under these circumstances.

Investigation Of Over The Counter (Otc ) Pharmaceutical Brands Prefered By New Age Indian Women

2019 ◽  
Vol 118 (4) ◽  
pp. 1-15
Author(s):  
Dr.G. Madhumita ◽  
Dr.G. Rajini ◽  
Dr.B. Subisha
Keyword(s):  
Pharmaceutical Company ◽  
Medical Practitioner ◽  
New Age ◽  
The Other ◽  
Pharmaceutical Companies ◽  
Brand Preference ◽  
Over The Counter ◽  
Indian Women ◽  
Prescription Medicines ◽  
Otc Medicines

The study investigates the preference of OTC Medicines among the pharmaceutical brand.OTC Medicines means medicines lawfully permitted to sell  “Over the Counter”, i.e. devoid of the prescription of a Registered Medical Practitioner. In India, although the expression has no lawful acknowledgment, all the medicines that are not incorporated in the list of ‘prescription only medicines’ are measured as non-prescription medicines (or OTC Medicines).Pharmaceutical over the counter products (OTC) be the medicines which can be sold without prescription. Also termed as “Non Prescription Medicines” discussed by Arti(2010).This article talks about top pharmaceutical company brands Aventis Pharma, GlaxoSmithKline, Surya Pharma, Torrent Pharma,Glenmark,Divis Labs,Biocon, Orchid Chemical, Abbott Indi, Sterling Bio, Alembic Pharma etc, the brand preference of New Age Indian Women. A 736 questionnaire was composed of different age and different New Age Indian Women in around Urban :Chennai ;Semi Urban :Neyveli ; Rural :Soolurpet ;Tirupur. The findings of the study shows that the highest preferred generic brand is balms,  Medicines chosen  for fever is Crocin, Idoex  is most ideal pain blams, volini spray is also most preferred brand, ENO is ideal Antacid brand, Sadiron is another chosen brand for cough and cold, the other brands are Metfal SPS, Johnson, Revital are the other favored brands. The study will be a great instrument for the pharmaceutical companies brands to understand today’s New Age Indian Women.

PP18 An Access Evidence IT Solution Within A Pharmaceutical Company

2018 ◽  
Vol 34 (S1) ◽  
pp. 72-73
Author(s):  
Marlene Gyldmark ◽  
Rachel Rosenthal ◽  
Martin Granser ◽  
Jasmin Escher-Kirch
Keyword(s):  
Pharmaceutical Company ◽  
Market Access ◽  
Pilot Project ◽  
Core Model ◽  
Regional Market ◽  
External Stakeholders ◽  
User Friendly ◽  
Further Development ◽  
Fast Access ◽  
Major Pharmaceutical Company

Introduction:During 2014, Roche tested whether the EUnetHTA HTA Core Model© was a useful, exhaustive and relevant value framework to promote efficiencies in scoping, storing and sharing health technology assessment (HTA) evidence within a pharmaceutical company. The conclusion was positive and Roche decided to build a cloud based information technology (IT) platform to store all relevant HTA evidence to support global and regional market access activities, tagged with metadata according to the HTA Core Model©., The platform should be user-friendly and promote efficiencies and knowledge sharing across the organization. Eventually this platform may also be used by external stakeholders to access relevant HTA evidence.Methods:In order to better equip global functions, regions and affiliates in a major pharmaceutical company with user-friendly and fast access to product-relevant HTA and payer evidence as well as access evidence plans, an easy-to-use IT-based platform was needed. The platform, internally called #TAg, is a central repository of information to support market access activities and promote collaboration between Affiliate, Region and Global teams. The platform uses metadata to label all types of evidence and uses the HTA Core Model© domains to categorize the evidence.Results:The platform #TAg was developed throughout 2016/2017 and officially launched on 1 October 2017. Within the first 30 days, the platform has been readily accepted by affiliates, regions and global functions through significant use uptake as measured by user registration and download activities. In addition, #TAg was used successfully in a pilot project for a submission to an external HTA body.Conclusions:A complete knowledge management system for HTA evidence is important for driving efficiency in scoping, storing and disseminating access evidence information within a pharmaceutical company. #TAg has so far proved a good start on such a system with further development expected in the coming years.

Bias at the Gate?: The Pharmaceutical Industry's Influence on the Federally Approved Drug Compendia

2014 ◽  
Vol 40 (1) ◽  
pp. 141-163
Author(s):  
Lindsey Gabrielsen
Keyword(s):  
Bipolar Disorder ◽  
Pharmaceutical Company ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
The Other ◽  
Insurance Companies ◽  
Off Label ◽  
Treatment Of Epilepsy ◽  
Clinical Indications ◽  
Federal Food

As of 2002, the Federal Food and Drug Administration (FDA) had approved Neurontin, a drug developed by the pharmaceutical company Pfizer, for two uses, the treatment of epilepsy and pain related to shingles. A staggering ninety-four percent of Neurontin prescriptions in the prior five years, however, were for other (non-FDA) approved uses. These other uses effectively tripled Medicaid’s costs for the drug between 1998 and 2003. Insurance companies covered the off-label uses because they appeared in the Drugdex compendium, a federally authorized listing of drugs that includes evidence regarding the drug’s effectiveness, clinical indications, and proper dosing. Drugdex included an additional forty-eight uses for Neurontin, ranging from bipolar disorder to the hiccups. Two other federally approved compendia existed at that time; one listed seven uses for Neurontin while the other listed only one.

scholarly journals Open Innovation: A New Mechanism For Adoption Of Organizational Innovation Empirical Evidence From Algerian Companies

2016 ◽  
Vol 4 (2) ◽  
pp. 11-22
Author(s):  
Khayra Aichouche ◽  
Rafika Bousalem
Keyword(s):  
Organizational Performance ◽  
Pharmaceutical Company ◽  
Empirical Evidence ◽  
Open Innovation ◽  
Organizational Innovation ◽  
Comprehensive Analysis ◽  
The Other ◽  
Conceptual Schema ◽  
The Relationship ◽  
Research Show

 The aim of this paper is to analyze the relationship between the openness degree of companies and organizational innovation. The openness degree is defined as the use of purposive inflows and outflows of knowledge to accelerate internal Innovation, and to expend markets for external use of innovation (Chesbrough, 2006). The research utilizes causality models and suggests a conceptual schema subsequent to a comprehensive analysis of the literature linked to open innovation field. A sample of 120 managers and employees of Algerian pharmaceutical company is used. The SEM is used to analyze and approve the proposal of the conceptual schema. Results of the empirical research show that open innovation is positively and significantly related to organizational innovation, on the other hand, these results indicate that there is a positive and significant impact of organizational innovation on organizational performance.

Development of an Orphan Drug by a Start-Up Company: MetroGel® for Rosacea

1992 ◽  
Vol 8 (4) ◽  
pp. 566-572 ◽  
Author(s):  
Robert J. Borgman
Keyword(s):  
United States ◽  
Research And Development ◽  
Pharmaceutical Company ◽  
Orphan Drug ◽  
The United States ◽  
Orphan Drug Act ◽  
Start Up ◽  
Significant Research ◽  
Marketing Costs ◽  
Major Pharmaceutical Company

AbstractThe Orphan Drug Act of 1983, along with the discovery of a new use for a known drug and an investor willing to assume the necessary risk, brought about the formation of a start-up pharmaceutical company. The primary incentive of the Orphan Drug Act of seven years of marketing exclusivity provided the protection from competition necessary for recovery of the significant research and development and marketing costs. The orphan product, MetroGel®, for the treatment of rosacea, required approximately five years of development before it was approved for marketing by the Food and Drug Administration. MetroGel® has become the number one drug in the United States for the treatment of rosacea. It currently is marketed in other countries through a licensing agreement with a major pharmaceutical company.

Stromatoporoids from the Famennian (Devonian) Wabamun Formation, Normandville oilfield, north–central Alberta, Canada

1988 ◽  
Vol 62 (03) ◽  
pp. 411-419 ◽  
Author(s):  
Colin W. Stearn
Keyword(s):  
Patch Reef ◽  
Abundant Species ◽  
The Other ◽  
North Central ◽  
Biotic Crisis

Stromatoporoids are the principal framebuilding organisms in the patch reef that is part of the reservoir of the Normandville field. The reef is 10 m thick and 1.5 km2in area and demonstrates that stromatoporoids retained their ability to build reefal edifices into Famennian time despite the biotic crisis at the close of Frasnian time. The fauna is dominated by labechiids but includes three non-labechiid species. The most abundant species isStylostroma sinense(Dong) butLabechia palliseriStearn is also common. Both these species are highly variable and are described in terms of multiple phases that occur in a single skeleton. The other species described areClathrostromacf.C. jukkenseYavorsky,Gerronostromasp. (a columnar species), andStromatoporasp. The fauna belongs in Famennian/Strunian assemblage 2 as defined by Stearn et al. (1988).

D. The Line Spectrum of Pulsating Variable Stars

1967 ◽  
Vol 28 ◽  
pp. 207-244
Author(s):  
R. P. Kraft
Keyword(s):  
Variable Stars ◽  
The Other ◽  
Line Spectrum ◽  
Afternoon Session ◽  
Empirical Information ◽  
Pulsating Variable Stars ◽  
Almost Continuous ◽  
Informal Approach

(Ed. note:Encouraged by the success of the more informal approach in Christy's presentation, we tried an even more extreme experiment in this session, I-D. In essence, Kraft held the floor continuously all morning, and for the hour and a half afternoon session, serving as a combined Summary-Introductory speaker and a marathon-moderator of a running discussion on the line spectrum of cepheids. There was almost continuous interruption of his presentation; and most points raised from the floor were followed through in detail, no matter how digressive to the main presentation. This approach turned out to be much too extreme. It is wearing on the speaker, and the other members of the symposium feel more like an audience and less like participants in a dissective discussion. Because Kraft presented a compendious collection of empirical information, and, based on it, an exceedingly novel series of suggestions on the cepheid problem, these defects were probably aggravated by the first and alleviated by the second. I am much indebted to Kraft for working with me on a preliminary editing, to try to delete the side-excursions and to retain coherence about the main points. As usual, however, all responsibility for defects in final editing is wholly my own.)

Sign in / Sign up

Export Citation Format

Share Document